Amgen's Repatha drug shows 37% sales growth, targeting a huge cardiovascular market opportunity.

Repatha lowers death risk by 20% in high-risk patients without prior heart attack or stroke.

Amgen's Repatha (evolocumab) significantly reduced all-cause and cardiovascular death risk by 20% in over 12,000 high-risk patients without previous heart attack or stroke, according to the Phase 3 VESALIUS-CV trial. The benefit emerged after 1.5 yea...